Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Pancreas Cancer
74%
Neoplasm
47%
Overall Survival
39%
Pembrolizumab
37%
Pancreas Islet Cell Tumor
32%
Stereotactic Body Radiation Therapy
27%
DNA Mismatch Repair
26%
Progression Free Survival
24%
Gemcitabine
24%
Disease
22%
Biological Marker
22%
Microsatellite Instability
21%
Adverse Event
18%
Surgery
18%
Immunohistochemistry
16%
Chemoradiotherapy
16%
Chemotherapy Agent
16%
Malignant Neoplasm
16%
Paclitaxel
14%
Solid Malignant Neoplasm
14%
Pancreatic Ductal Adenocarcinoma
13%
Immunotherapy
12%
Endometrial Cancer
11%
Immunosuppressive Treatment
11%
Neuroendocrine Tumor
11%
Quality of Life
10%
Recurrent Disease
10%
Personalized Medicine
10%
Arm
10%
Neoadjuvant Chemotherapy
10%
Adjuvant Therapy
9%
Hazard Ratio
9%
Stroma
8%
Disease Free Survival
8%
Cyclophosphamide
8%
Monotherapy
8%
Temozolomide
8%
Oncology
8%
Capecitabine
7%
Metastatic Carcinoma
7%
Patient Population
7%
Radiation Therapy
7%
CD8 Antigen
6%
Long Term Survival
6%
Induction Chemotherapy
6%
Neutrophil
6%
Cancer Stem Cell
6%
Lymphocyte
6%
Prognostic Factor
6%
Keyphrases
Pancreatic Ductal Adenocarcinoma
48%
Pembrolizumab
37%
Pancreatic Cancer
37%
Overall Survival
32%
Metastatic Pancreatic Ductal Adenocarcinoma
30%
Confidence Interval
28%
Pancreatic Neuroendocrine Tumors (pNETs)
27%
Microsatellite Instability-high (MSI-H)
27%
Mismatch Repair
27%
Resectable Pancreatic Cancer
25%
Tumor
25%
Irinotecan
23%
Clinical Outcomes
22%
Previously Treated
21%
Pancreatic Adenocarcinoma
20%
Stereotactic Body Radiation Therapy
20%
Deficient Mismatch Repair (dMMR)
19%
Metastatic Pancreatic Adenocarcinoma
16%
Single Institution
16%
Chemotherapy
16%
Neoadjuvant
16%
Gemcitabine
16%
Progression-free Survival
16%
Chemoradiation
16%
Phase II Study
16%
Median Overall Survival
16%
Survival Outcomes
15%
Chemotherapy Alone
13%
Non-colorectal
13%
Disease-free Survival
12%
Cisplatin
12%
Borderline Resectable
12%
Induction Chemotherapy
11%
Advanced Solid Tumors
11%
Health-related Quality of Life
11%
Multiagent Chemotherapy
11%
Hazard Ratio
11%
Upfront Chemotherapy
10%
Neoadjuvant Chemotherapy
10%
Microsatellites
10%
Endometrial Cancer
10%
Nal-IRI
10%
Adjuvant Therapy
9%
Objective Response Rate
9%
Colorectal Cancer
9%
Pancreas
9%
Newly Diagnosed
9%
Treatment-related Adverse Events
9%
QLQ-C30
8%
Johns Hopkins Hospital
8%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
59%
Pancreas Cancer
53%
Chemotherapy
41%
Overall Survival
34%
Neoplasm
32%
Irinotecan
29%
Pembrolizumab
27%
Progression Free Survival
25%
Gemcitabine
23%
Malignant Neoplasm
18%
Adverse Event
17%
Capecitabine
15%
Chemoradiation Therapy
15%
Cisplatin
13%
Biological Marker
12%
Disease
11%
Endometrium Cancer
11%
Neuroendocrine Tumor
11%
Immunoreactive Insulin
10%
Paclitaxel
9%
Temozolomide
9%
Immunotherapy
8%
Monotherapy
7%
Carcinoembryonic Antigen
7%
Fluorouracil
6%
Solid Malignant Neoplasm
6%
Docetaxel
6%
Chemotherapy Agent
6%
Tumor Microenvironment
5%
Lutetium 177
5%
N (6,7 Dihydro 6 Oxo 5h dibenz[b,d]azepin 7 Yl) 2,2 Dimethyl N' (2,2,3,3,3 Pentafluoropropyl)propanediamide
5%
Pseudotumor
5%
Antigen
5%
Phase I Trials
5%
Metformin
5%
Rapamycin
5%
Erlotinib
5%
Carcinoma
5%
Brain Tumor
5%
Focal Adhesion Kinase
5%
Metastatic Colorectal Cancer
5%
Colorectal Cancer
5%
Lymph Node Metastasis
5%
Colon Cancer
5%
Cytomegalovirus
5%
Vismodegib
5%
Mitomycin
5%
Guadecitabine
5%
Opportunistic Infection
5%
Fibrosis
5%
